rs121913530
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
|
23182985 |
2013 |
rs17851045
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
|
23325582 |
2013 |
rs17851045
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
|
23325582 |
2013 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
|
22734028 |
2012 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
|
22392911 |
2012 |
rs121913530
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
|
22722830 |
2012 |
rs17851045
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
|
22722830 |
2012 |
rs17851045
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
|
22722830 |
2012 |
rs1057519725
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs112445441
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
|
21398618 |
2011 |
rs121913238
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs121913240
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs121913240
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs121913527
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs121913528
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
|
21398618 |
2011 |
rs121913529
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs121913529
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs121913529
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
|
21398618 |
2011 |
rs121913529
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs121913530
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs121913530
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs121913530
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs121913535
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |